- Healthcare Professionals
- Research
- Clinical trials
- Optimapharm - ADELA study
2025-01-01T00:00:00.000+00:00
Ongoing
Optimapharm - ADELA study
Optimapharm - ADELA study
Chronic Lymphocytic Leukaemia
A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors. (The ADELA Study)
A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors. (The ADELA Study)
Trial overview
Disease
Breast cancer
Topic
Interventional
Sponsor
MedSIR
Description
A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors. (The ADELA Study)
Study details
For detailed information on this trial, please click here
Trial status
Opening January 2025
Location
Oxford
:::
Principal Investigator
